UBS Group’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.1M | Sell |
67,400
-69,600
| -51% | -$37.8M | 0.01% | 2069 |
|
|
2025
Q4 | $79.4M | Sell |
137,000
-124,000
| -48% | -$70.1M | 0.01% | 1198 |
|
|
2025
Q3 | $127M | Buy |
261,000
+71,300
| +38% | +$33.2M | 0.02% | 869 |
|
|
2025
Q2 | $76.9M | Buy |
189,700
+43,400
| +30% | +$18.1M | 0.01% | 1154 |
|
|
2025
Q1 | $72.8M | Buy |
146,300
+31,500
| +27% | +$17.1M | 0.01% | 1146 |
|
|
2024
Q4 | $59.7M | Sell |
114,800
-209,316
| -65% | -$115M | 0.01% | 1306 |
|
|
2024
Q3 | $200M | Buy |
324,116
+240,116
| +286% | +$142M | 0.04% | 413 |
|
|
2024
Q2 | $46.5M | Sell |
84,000
-30,500
| -27% | -$17.5M | 0.01% | 1086 |
|
|
2024
Q1 | $66.5M | Sell |
114,500
-34,102
| -23% | -$19.1M | 0.02% | 863 |
|
|
2023
Q4 | $78.9M | Buy |
148,602
+96,102
| +183% | +$46.5M | 0.02% | 704 |
|
|
2023
Q3 | $26.6M | Buy |
52,500
+19,300
| +58% | +$10.3M | 0.01% | 1277 |
|
|
2023
Q2 | $17.3M | Buy |
33,200
+21,500
| +184% | +$11.6M | 0.01% | 1559 |
|
|
2023
Q1 | $6.74M | Sell |
11,700
-31,500
| -73% | -$17.8M | ﹤0.01% | 2235 |
|
|
2022
Q4 | $23.8M | Buy |
43,200
+32,400
| +300% | +$17.2M | 0.01% | 1288 |
|
|
2022
Q3 | $5.48M | Buy |
10,800
+4,200
| +64% | +$2.35M | ﹤0.01% | 2276 |
|
|
2022
Q2 | $3.58M | Sell |
6,600
-20,700
| -76% | -$11.4M | ﹤0.01% | 2654 |
|
|
2022
Q1 | $16.1M | Sell |
27,300
-24,300
| -47% | -$14M | 0.01% | 1602 |
|
|
2021
Q4 | $34.4M | Buy |
51,600
+610
| +1% | +$381K | 0.01% | 1198 |
|
|
2021
Q3 | $29.1M | Buy |
50,990
+14,600
| +40% | +$8.01M | 0.01% | 1206 |
|
|
2021
Q2 | $18.4M | Buy |
36,390
+3,600
| +11% | +$1.7M | 0.01% | 1554 |
|
|
2021
Q1 | $15M | Buy |
32,790
+790
| +2% | +$377K | 0.01% | 1637 |
|
|
2020
Q4 | $14.9M | Buy |
32,000
+31,600
| +7,900% | +$14.8M | 0.01% | 1550 |
|
|
2020
Q3 | $177K | Sell |
400
-20,900
| -98% | -$8.63M | ﹤0.01% | 4859 |
|
|
2020
Q2 | $7.72M | Buy |
21,300
+6,000
| +39% | +$2.01M | ﹤0.01% | 1716 |
|
|
2020
Q1 | $4.34M | Sell |
15,300
-12,500
| -45% | -$3.94M | ﹤0.01% | 2053 |
|
|
2019
Q4 | $9.03M | Buy |
27,800
+12,500
| +82% | +$3.79M | ﹤0.01% | 2045 |
|
|
2019
Q3 | $4.46M | Sell |
15,300
-19,400
| -56% | -$5.56M | ﹤0.01% | 2495 |
|
|
2019
Q2 | $10.2M | Buy |
34,700
+34,000
| +4,857% | +$9.36M | ﹤0.01% | 1741 |
|
|
2019
Q1 | $192K | Sell |
700
-29,900
| -98% | -$7.44M | ﹤0.01% | 4623 |
|
|
2018
Q4 | $6.85M | Buy |
30,600
+20,800
| +212% | +$4.88M | ﹤0.01% | 1888 |
|
|
2018
Q3 | $2.39M | Sell |
9,800
-19,200
| -66% | -$4.42M | ﹤0.01% | 3058 |
|
|
2018
Q2 | $6.01M | Buy |
29,000
+28,800
| +14,400% | +$6.11M | ﹤0.01% | 2181 |
|
|
2018
Q1 | $41K | Buy |
+200
| New | +$42K | ﹤0.01% | 5867 |
|
|
2017
Q4 | – | Sell |
-100
| Closed | -$19K | – | 8098 |
|
|
2017
Q3 | $19K | Sell |
100
-600
| -86% | -$109K | ﹤0.01% | 6499 |
|
|
2017
Q2 | $122K | Buy |
700
+400
| +133% | +$67.2K | ﹤0.01% | 5045 |
|
|
2017
Q1 | $46K | Sell |
300
-200
| -40% | -$30.6K | ﹤0.01% | 5583 |
|
|
2016
Q4 | $71K | Sell |
500
-6,000
| -92% | -$885K | ﹤0.01% | 5555 |
|
|
2016
Q3 | $1.03M | Buy |
+6,500
| New | +$1M | ﹤0.01% | 3400 |
|
|
2016
Q2 | – | Sell |
-500
| Closed | -$71K | – | 7971 |
|
|
2016
Q1 | $71K | Buy |
+500
| New | +$67K | ﹤0.01% | 5231 |
|
|
2015
Q4 | – | Sell |
-500
| Closed | -$61K | – | 8577 |
|
|
2015
Q3 | $61K | Sell |
500
-800
| -62% | -$104K | ﹤0.01% | 5652 |
|
|
2015
Q2 | $169K | Buy |
+1,300
| New | +$169K | ﹤0.01% | 5014 |
|
|
2015
Q1 | – | Sell |
-85,200
| Closed | -$10.7M | – | 9373 |
|
|
2014
Q4 | $10.7M | Buy |
+85,200
| New | +$10.4M | 0.01% | 1456 |
|
Other funds holding TMO
VCM
UBS Group's TMO Position: Q1 2026 in Review
UBS Group increased its Thermo Fisher Scientific (TMO) stake by 5.6% in Q1 2026, buying an estimated $70.6M and bringing the position to 2,453,453 shares worth $1.21B. The position accounts for 0.18% of the portfolio, ranked #104.
UBS Group first reported a position in TMO in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.58B in Q3 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- UBS Group held 2,453,453 shares of Thermo Fisher Scientific worth $1.21B as of Q1 2026.
- UBS Group bought 130,110 Thermo Fisher Scientific shares in Q1 2026, an estimated $70.6M.
- Thermo Fisher Scientific made up 0.18% of UBS Group's portfolio in Q1 2026, its #104 holding.
- UBS Group first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Thermo Fisher Scientific position peaked at $1.58B in Q3 2024.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.